Listen to this episode on:
In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development.
Key topics include:
- The evolution of atai Life Sciences, from a fund to a biotech company.
- Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter.
- Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
- Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
- Tackling clinical trial challenges, including the placebo effect and trial design complexities.
Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.